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Abstract
Prospective studies are key study designs when attempting to unravel health mechanisms
that are widely applicable. Understanding the internal validity of a prospective study is
essential to judge a study’s quality. Moreover, insights in possible sampling bias and the
external validity of a prospective study are useful to judge the applicability of a study’s find-
ings. We evaluated participation, retention, and associated factors of women in a multicen-
ter prospective cohort (FemCure) to understand the study’s validity.Chlamydia trachomatis
(CT) infected adult women, negative for HIV, syphilis, and Neisseria gonorrhoeae were eligi-
ble to be preselected and included at three sexually transmitted infection (STI) clinics in the
Netherlands (2016–2017). The planned follow-up for participants was 3 months, with two
weekly rectal and vaginal CT self-sampling and online questionnaires administered at home
and at the clinic. We calculated the proportions of preselected, included, and retained (com-
pleted follow-up) women. Associations with non-preselection, noninclusion, and non-reten-
tion (called attrition) were assessed (logistic and Cox regression).Among the 4,916 women,
1,763 (35.9%) were preselected, of whom 560 (31.8%) were included. The study population
had diverse baseline characteristics: study site, migration background, high education, and
no STI history were associated with non-preselection and noninclusion. Retention was
76.3% (n = 427). Attrition was 10.71/100 person/month (95% confidence interval 9.97,
12.69) and was associated with young age and low education. In an outpatient clinical set-
ting, it proved feasible to include and retain women in an intensive prospective cohort.
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External validity was limited as the study population was not representative (sampling bias),
but this did not affect the internal validity. Selective attrition, however (potential selection
bias), should be accounted for when interpreting the study results.
Introduction
Prospective studies are key study designs for assessing the risks of certain determinants in
acquiring a specific disease in an attempt to unravel health mechanisms that are widely appli-
cable [1,2]. Women’s participation in prospective studies is fundamental to understanding
their health mechanisms [3]. Despite a continued emphasis by regulatory bodies, health insti-
tutions, research funding organizations, and scientific journals, the inclusion of women in
research is not easy [4,5]. Significant benefits for prospective research in women can be reaped
by sharing best practices on inclusion and retention.
First and foremost, a prospective study should have high internal validity to generate
unconfounded insights [1]. Understanding a study’s internal validity is essential to judging its
quality. Internal validity may be compromised when it is difficult to include sufficient partici-
pants. Low study power may result in associations that are spurious (“false”), imprecise (with
wide confidence intervals), or missed altogether [6,7], and it becomes difficult to replicate the
study. Similar threats to internal validity arise when insufficient participants are retained, i.e.,
when a large portion of included women is lost to follow-up or withdraws from the study
(both called attrition). When attrition disproportionally affects a subset of the study popula-
tion, it may lead to selection bias and an underestimation or an overestimation of the associa-
tions [1,8].
When a prospective study has high internal validity, the risks obtained may be applicable to
a broad population of women and the study population does not need to have high external
validity, i.e., be a representative sample [9–11]. Usually, representative frequency distributions
are derived from other types of research, i.e., population-based surveys [9]. In practice, it has
proven to be logistically difficult and cost ineffective to include and follow a representative
sample in a study that, first and foremost, is designed to achieve high internal validity [12].
Still, insights in possible sampling bias and the external validity of a prospective study are use-
ful to judge the applicability of a study’s findings. Internal and external validity reporting has
improved with the STROBE and CONSORT guidelines [13] and is increasingly encouraged in
the scientific journals [14].
Here, we report on the FemCure study, the first prospective research that systematically
addresses rectal Chlamydia trachomatis (CT) in women [15]. FemCure included 560 women
from three Dutch STI clinics and followed them for 3 months with systematic rectal and vagi-
nal CT assessment. Chlamydia infection is the most commonly reported treatable bacterial
sexually transmitted infection (STI) in high-income countries [16,17]. CT disproportionally
affects women in terms of its occurrence and burden of sequelae, i.e., pelvic inflammatory dis-
ease, ectopic pregnancy, and tubal infertility [18]. The main treatments are doxycycline and
azithromycin [19,20], although, the efficacy of azithromycin in the treatment of CT is debat-
able [21]. FemCure was set up to improve our understanding of posttreatment rectal and vagi-
nal CT detection in women, by assessing risks due to sexual exposure (horizontal
transmission) or exposure from adjacent body sites (self-infection), and by assessing the role
of possibly suboptimal treatment effectiveness [15].
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Here, we describe the multifaceted strategies that were implemented to include and retain a
group of women attending STI clinics in a prospective cohort study. Insights in potential sam-
pling bias and external validity of the FemCure study population as well as potential selection
bias of the retained sample (internal validity) are presented by analyzing the factors associated
with nonparticipation and attrition.
Materials and methods
Ethics approval and consent to participate
All participants provided written informed consent. This study was approved by the Medical
Ethical Review Committee from the Maastricht University Medical Centre, Maastricht Nether-
lands (NL51358.068.15/METC153020, 20-01-2016) and monitored by the Clinical Trial Centre
Maastricht. ClinicalTrials.gov Identifier: NCT02694497.
Study design
STI clinic setting for the study. The study population originated from the STI clinics of
the Public Health Services in South Limburg, Rotterdam, and Amsterdam, which represent
almost half of all STI clinic consultations in the Netherlands. Clinics apply the same care pro-
cedures [19] but vary in their annual number of clients (6,000–45,000) and urbanization
degree (rural to highly urban) [22]. According to European guidelines [19], all women were
tested for vaginal CT, and they were also rectally tested, when reporting anal sex or anal symp-
toms. Women who tested positive for rectal infection were treated with a seven-day course of
oral doxycycline 100 mg twice daily [19]. Women who tested positive for vaginal infection,
and who either tested negative for rectal infection or did not undergo the rectal test, received a
1 g single azithromycin oral dose. The first doxycycline and azithromycin doses were directly
observed. In this context, we set up a cohort study with 3 months of follow-up (Fig 1) [15].
Target population. The target population of FemCure were women, who were 18 years
or older, diagnosed with a vaginal or rectal CT infection during the inclusion period (April
2016 until September 2017), and negative for HIV, syphilis, and Neisseria gonorrhoeae (NG).
FemCure aimed to have at least 400 women with complete follow-up, for sufficient power for
the planned analyses [15]. To maximize participation, multifaceted strategies focused on help-
ful themes, identified previously [23–31], were simultaneously implemented (Table 1).
Who was preselected for inclusion?. Study information was provided to the women at
least a day before the inclusion visit (the treatment consultation), to give them time to make an
informed decision. Therefore, a standardized text and link to the study’s website were commu-
nicated via the routine channels that clinics use for contacting patients (i.e., online and by text
message). Women from the target population could be preselected at the treatment consulta-
tion when the following applied: (a) a research nurse was available at that moment to handle
inclusion (the predefined research capacity for handling study visits was four to six nurses per
clinic; nurses were required to be available part-time for study duties, a priori restricting the
number of patients who could be preselected); (b) study criteria applied (no recent antibiotic
use, not pregnant, received study information at least 1 day before participation, understand
the Dutch language, able to complete the study [e.g., not going abroad during the study, living
close to the clinic]); (c) the patient was willing to, at that moment, be fully informed about the
study and, when accepting inclusion, to comply with the study procedures; (d) the patient was
willing to be transferred to a research nurse for possible inclusion in case if the patient was not
already managed by a research nurse.
Who was included in the study?. For preselected women, the research nurse provided
information and checked study criteria. A calendar was used to plan follow-up clinic visits.
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When a patient accepted the study procedures, providing written informed consent, the
research nurse handled inclusion and provided treatment. Reasons for noninclusion were
scored.
Who was followed after inclusion?. All included women were followed, but they could
withdraw from the study or become lost-to-follow-up (both: attrition). Reasons for study with-
drawal were recorded.
Data collection. Clinical data (such as baseline characteristics of the target population)
originated from the electronic clinic patient registries. Participants in the study self-collected
rectal and vaginal samples for CT testing and completed structured online self-administered
questionnaires (on antibiotic use, symptoms, and sexual behavior) at inclusion (week 0), and
at weeks 4, 8, and 12 at the STI clinic, and at weeks 1, 2, 6, and 10 at home (Fig 1). A test pack-
age with clear instructions was provided for self-collection of samples at home. Week 12 data
also included a study evaluation.
Statistical analyses
Aim and outcomes. For the current analysis, we aimed to elucidate aspects of internal
and external validity of the FemCure study. We analyzed participation (preselection, inclu-
sion) and retention, and factors (patient characteristics) associated with nonparticipation
(non-preselection, noninclusion) and attrition.
Fig 1. Design of the prospective cohort study, FemCure.
https://doi.org/10.1371/journal.pone.0230413.g001
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Table 1. Themes and strategies (derived from previous studies 23–31) employed in the prospective multicenter
FemCure study, aimed to maximize women’s participation.
Themes Strategies
Allow long preparation phase • Acquire funding, acquire institutional review board approval,
install logistical requirements, install management systems, and
train all staff
Easy access to the study population • Low-threshold STI clinics ensured a continuous availability of
chlamydia-infected adult women.
• Before inclusion of potential participants, eligibility was
prechecked by the clinic nurses.
Clear study information for patients • Study information was provided to women at least a day before
the inclusion visit, to give time for an informed decision.
• A public website was launched with study information and
procedures (www.FemCure.nl).
• The research nurses were available to explain the study during
face-to-face contact.
Study theme relevant for the patient • The study addressed the health problem (vaginal and/or rectal
chlamydia) that patients had.
Easy data collection • Women could participate from their homes and in the vicinity of
their homes, i.e., at the STI clinic where they initially went for their
STI testing.
• For women with transportation constraints, financial
compensation was provided to cover transport costs.
• Kits for self-sampling and online questionnaires enabled data
collection at the patient’s own pace in the privacy of their home.
• Participants received study material, instructions, and a personal
booklet with all study appointments.
• At each STI clinic study visit, the nurse provided face-to-face
clarification when needed.
Familiar and close-contact environment • The study setting and procedures were fully integrated into a
clinical setting, which the participants were already familiar with.
• Follow-up visits of the participant were scheduled as much as
possible with the same nurse who included the woman.
• Participants could be contacted by (or herself contact) the
research nurse in case of questions. A study-specific mobile
telephone and email address were used and monitored several
times each day to ensure timely responses to participants.
• Short text messages were used to remind the women to complete
the questionnaire and take the self-samples. Women who did not
respond were contacted multiple times.
Incentives for patients • At each clinic visit, the participants received a small 10-euro gift
certificate.
At the last clinic visit, each participant was offered oral, vaginal,
and rectal CT/NG testing, and treatment when needed, free of
charge.
High-functioning staff: research nurses
(n = 18)
• Handled the inclusion and follow-up study-visits at weeks 0, 4, 8,
and 12 at the three study sites.
• Highly experienced in STI care, available part-time for study
duties and part-time for routine clinic duties.
• Fully trained for the study procedures, online questionnaires,
and for good clinical practices.
• Sufficient time was allocated to handle the patient visits.
• Daily local supervision by dedicated site coordinators and
available back-office staff to provide support in case of questions.
• Interim site meetings were organized to discuss inclusion,
retention, facilitators, and barriers.
(Continued)
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Participation. Preselection was the proportion of women preselected from the target pop-
ulation. Inclusion was the proportion included from the preselected women and the propor-
tion of women included from the target population.
Retention. Retention was the proportion of included women who attended the week 12
visit. Kaplan–Meier techniques with 95% confidence intervals (95% CI) were used to show
retention over time.
Non-participation. Non-preselection and noninclusion were assessed as proportions.
Attrition. Attrition, i.e., withdrawal or lost-to-follow-up, was assessed as a rate (per 100
person months [PM]) and 95% CI.
Factors evaluated. Characteristics at baseline were: study site (South Limburg, Rotter-
dam, Amsterdam), age (18–20, 21–23,�24 years), migration background (Western, Asian/
Turkish, African, Latin America, unknown), education (low, middle, high, unknown), STI his-
tory (yes, no, unknown), diagnosed CT (vaginal [and rectal untested], vaginal [and rectal nega-
tive], vaginal and rectal, rectal [and vaginal negative]), number of sex partners in the past 6
months (0 or 1, 2 or 3,� 4, unknown). The educational level was measured as current educa-
tion or highest educational level completed and was categorized into three categories: lower
educated (pre-vocational secondary education, secondary vocational education), medium edu-
cated (senior general secondary education, pre-university education) and higher educated
(higher professional education, university education).
Associations with nonparticipation. To examine potential selective participation and
explore sampling bias, associated factors for non-preselection in the target population, and for
noninclusion among preselected women, were assessed by univariate and multivariate logistic
regression analyses using a stepwise backward approach, and expressed by odds ratios (OR)
and 95% CI. Associated factors for noninclusion were also assessed in the target population to
explore the representativeness of the study population.
Table 1. (Continued)
Themes Strategies
High-functioning staff: logistical staff (n = 6) • Handled retention activities using a well-built data management
system. Reminder text messages were sent daily. Additional
contact attempts were via phone and via email. Research nurses
were contacted when needed.
• Back office. A special email address and a secure internet
environment were created to allow safe communication between
staff.
• Regular transport of collected stored samples from the study sites
to the coordinating laboratory (Maastricht).
• Gave feedback on progress in order to optimize procedures,
inclusion, and retention.
• Fully trained in the study procedures, good clinical practice, and
management activities.
High-functioning staff: laboratory staff (n = 5) • Handled sample registration, storage, laboratory testing, and
provision of information to the data manager.
High-functioning staff: project coordinator
(n = 1) and site coordinators (n = 3)
• Monitored inclusion and retention throughout the study to
ensure that targeted goals were met.
• Supervised the overall processes in conjunction with the site
coordinators and also handled institutional review board and
study oversight.
CT: Chlamydia trachomatis; NG: Neisseria gonorrhoeae; STI: sexually transmitted infections
https://doi.org/10.1371/journal.pone.0230413.t001
PLOS ONE Participation of women in prospective chlamydia research
PLOS ONE | https://doi.org/10.1371/journal.pone.0230413 March 18, 2020 6 / 17
Associations with attrition. To examine potential selective attrition and explore selection
bias, factors associated with attrition risk were assessed using univariate and multivariate Cox
regression analyses and expressed by hazard ratios (HR) and 95% CI.
Descriptive statistics. Descriptive statistics were used for the distribution of the patient
characteristics and for the reasons for noninclusion or attrition. For the retained women, we
described the number of missing samples and questionnaires, and the women’s week 12 study
evaluation responses.
Statistical software. We used the IBM SPSS Statistics 21 and Stata StataCorp 15.
Results
Target population
In the study period, 4,916 women who were eligible for preselection came to the participating
clinics (Table 2).
Participation
Preselection. Among the 4,916 women, 1,763 (35.9%) were preselected.
Inclusion. Among the preselected women, 560 (31.8%) were included (Table 2). Included
women comprised 11.4% of the target population. Table 2 presents the baseline characteristics
distribution in different steps from the target population to the included population. Among
the included women, 28.9% were young (18–20 years), 36.3% had a low educational level, and
7.7% had a non-Western migration background.
Retention
Among the included women, 427 (76.2%) were retained (Fig 2, Table 2). Together, these 427
women collected data 3,416 scheduled times. By the seventeenth scheduled time (0.5%, 15
women), samples and questionnaire data were not provided in 3 of these moments. Further, at
14 moments, questionnaire data were not provided.
Nonparticipation
Non-preselection. Among the 4,916 women in the target population, 3,153 (64.1%) were
not preselected.
Noninclusion. Among the 1,763 preselected women, 1,203 (68.2%) were not included.
Reasons for noninclusion were related to study criteria in 556 of the not included women,
i.e., unable to attend clinic visits as required (n = 450), insufficient understanding of the Dutch
language (n = 41), not accepting directly observed treatment (n = 48), or sample collection at
home (n = 17). A total of 590 women were not included due to patient-related reasons (too
much expected effort or time). There were 57 patients who declined due to other reasons or
did not provide a reason.
Attrition
Among the 560 included women, 133 withdrew from the study or were lost-to-follow-up. The
attrition rate was 10.71/100 PM (95% CI 9.97, 12.69). Women who were lost to follow up
(n = 66) did not differ in their baseline characteristics (P>0.05 by two-sided chi-squared test-
ing) compared to women who withdrew (n = 67). Women who withdrew stated they were
incapable or unwilling to invest further time in the study (n = 43) or had other reasons
(n = 24). Reasons for stopping sample provision were unknown when women were lost to fol-
low up as they did not respond to the text messages or telephone calls of the research nurse.
PLOS ONE Participation of women in prospective chlamydia research
PLOS ONE | https://doi.org/10.1371/journal.pone.0230413 March 18, 2020 7 / 17
Factors associated with nonparticipation
Associated factors for non-preselection from the target population. In the multivariate
analyses (Table 3), factors independently associated with non-preselection were study site
Amsterdam (compared to South Limburg), non-Western migration background, and no STI his-
tory. A medium educational level (compared to a low educational level) was inversely associated.
Table 2. Baseline characteristics distributions in the target population, (not) preselected women, (not) included women, and women retained in the study,
FemCure.
Target population (N = 4,916) a Preselected women (N = 1,763)
Total
N = 4,916
Not preselected
N = 3,153
Preselected
N = 1,763
Preselected not included
N = 1,203
Included
N = 560
Included and retained
N = 427
n (%) n (%) n (%) n (%) n (%) n (%)
Study site
South Limburg 974 (19.8) 504 (16.0) 470 (26.7) 271 (22.5) 199 (35.5) 154 (36.1)
Amsterdam 2,875 (58.5) 2,099 (66.6) 776 (44.0) 579 (48.1) 197 (35.2) 156 (36.5)
Rotterdam 1,067 (21.7) 550 (17.4) 517 (29.3) 353 (29.3) 164 (29.3) 117 (27.4)
Age (in years)
18–20 1,382 (28.1) 853 (27.1) 529 (30.0) 367 (30.5) 162 (28.9) 105 (24.6)
21–23 1,935 (39.4) 1,221 (38.7) 714 (40.5) 510 (42.4) 204 (36.4) 161 (37.7)
�24 1,599 (32.5) 1,079 (34.2) 520 (29.5) 326 (27.1) 194 (34.6) 161 (37.7)
Background
Western 3,962 (80.6) 2,476 (78.5) 1,486 (84.3) 969 (80.5) 517 (92.3) 400 (93.7)
Asian/Turkish
migrant
186 (3.8) 123 (3.9) 63 (3.6) 48 (4.0) 15 (2.7) 10 (2.3)
African migrant 222 (4.5) 149 (4.7) 73 (4.1) 61 (5.1) 12 (2.1) 10 (2.3)
Latin American
migrant
545 (11.1) 405 (12.8) 140 (7.9) 124 (10.3) 16 (2.9) 7 (1.6)
Unknown b 1 (0.0) 0 (0) 1 (0.1) 1 (0.1) 0 (0) 0 (0)
Education
Low 1,513 (30.8) 941 (29.8) 572 (32.4) 369 (30.7) 203 (36.3) 135 (31.6)
Middle 661 (13.4) 327 (10.4) 334 (18.9) 127 (10.6) 207 (37.0) 160 (37.5)
High 2,533 (51.5) 1,705 (54.1) 828 (47.0) 679 (56.4) 149 (26.6) 131 (30.7)
Unknown 209 (4.3) 180 (5.7) 29 (1.6) 28 (2.3) 1 (0.2) 1 (0.2)
STI history
Yes 743 (15.1) 403 (12.8) 340 (19.3) 175 (14.5) 165 (29.5) 124 (29.0)
No 3,031 (61.7) 2,017 (64.0) 1014 (57.5) 626 (52.0) 388 (69.3) 297 (69.6)
Unknown b 1,142 (23.2) 733 (23.2) 409 (23.2) 402 (33.4) 7 (1.3) 6 (1.4)
CT diagnosis
vCT (rCT not tested) 2,880 (58.6) 1,760 (55.8) 1,120 (63.5) 769 (63.9) 351 (62.7) 264 (61.8)
vCT (rCT negative) 273 (5.6) 188 (6.0) 85 (4.8) 60 (5.0) 25 (4.5) 19 (4.4)
vCT & rCT 1,458 (29.7) 991 (31.4) 467 (26.5) 312 (25.9) 155 (27.7) 118 (27.6)
rCT (vCT negative) 305 (6.2) 214 (6.8) 91 (5.2) 62 (5.2) 29 (5.2) 26 (6.1)
No. of sex partners
0 or 1 1,158 (23.6) 762 (24.2) 396 (22.5) 270 (22.4) 126 (22.5) 95 (22.2)
2 or 3 2,242 (45.6) 1,388 (44.0) 854 (48.4) 587 (48.8) 267 (47.7) 194 (45.4)
� 4 1,486 (30.2) 987 (31.3) 499 (28.3) 334 (27.8) 165 (29.5) 136 (31.9)
unknown b 30 (0.6) 16 (0.5) 14 (0.8) 12 (1.0) 2 (0.4) 2 (0.5)
rCT: rectal Chlamydia trachomatis, vCT: vaginal Chlamydia trachomatis
a Women 18 years or older with vaginal or rectal CT and negative for HIV, syphilis, and Neisseria gonorrhoeae, during the study inclusion period: Apr. 2016–Sept. 2017
b missing information
https://doi.org/10.1371/journal.pone.0230413.t002
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Associated factors for noninclusion from preselected women. In the multivariate analy-
ses (Table 3), factors independently associated with noninclusion in the preselected women
were study site Amsterdam (compared to South Limburg), non-Western migration back-
ground, no STI history, being 18–20 years of age (compared to 24 years or older) and a high
educational level (rather than a low educational level). A medium educational level (compared
to low education) was inversely associated.
Associated factors for noninclusion from the target population. In the multivariate
analyses (Table 3), factors independently associated with noninclusion were study site Amster-
dam (compared to South Limburg), non-Western migration background, no STI history, and
a high educational level (compared to low education). A medium educational level (compared
to low educational level) was inversely associated.
Factors associated with attrition risk
The attrition risk was higher in women with low educational level (compared to high educa-
tional level) and in women aged 18–20 years (compared to 24 years or older) (Table 4).
Fig 2. Kaplan–Meier survival function (line) with 95% confidence intervals (grey area) on the probability of being retained, and the number of women
retained (“Number at Risk”) in the FemCure study.
https://doi.org/10.1371/journal.pone.0230413.g002
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Table 3. Odds ratios for the association between characteristics and non-preselection among STI clinic women target population, and noninclusion among prese-
lected women, and noninclusion among the target population, FemCure.
Non-preselection from target population a Noninclusion from preselected women a Noninclusion from target population a
OR (95% CI) P aOR (95% CI) P OR (95% CI) p aOR (95% CI) P OR (95% CI) P aOR (95% CI) P
Study site <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
South Limburg 1 1 1 1 1 1
Amsterdam 2.52
(2.17,2.93)
3.70
(3.06,4.47)
2.16
(1.69,2.76)
4.45
(3.20,6.21)
3.49
(2.82,4.32)
7.66
(5.90,9.95)
Rotterdam 0.99
(0.83,1.18)
0.92
(0.76,1.11)
1.58
(1.22,2.05)
1.37
(0.95,1.98)
1.41
(1.13,1.78)
1.30
(0.98,1.73)
Age (in years) <0.01 <0.01 <0.01 0.30
18–20 0.78
(0.67,0.90)
1.35
(1.04,1.74)
3.65
(2.53,5.27)
1.04
(0.83,1.30)
21–23 0.82
(0.72,0.95)
1.49
(1.17,1.89)
3.10
(2.25,4.27)
1.17
(0.95,1.44)
�24 1 1 1 1
Background <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Western 1 1 1 1 1 1
Non west. Migrant 1.47
(1.26,1.72)
1.32
(1.12,1.57)
2.89
(2.05,4.07)
3.03
(2.00,4.58)
3.18
(2.31,4.37)
2.84
(2.00,4.04)
Unknown b
Education <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Low 1 1 1 1 1 1
Middle 0.60
(0.50,0.72)
0.52
(0.43,0.64)
0.34
(0.26,0.45)
0.28
(0.19,0.40)
0.34
(0.27,0.42)
0.32
(0.25,0.42)
High 1.25
(1.10,1.43)
1.01
(0.87,1.17)
2.51
(1.96,3.21)
3.09
(2.24,4.45)
2.48
(2.00,3.10)
2.20
(1.71,2.83)
Unknown b na
STI history <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Yes 1 1 1 1 1 1
No 1.68
(1.43,1.98)
1.24
(1.04,1.48)
1.52
(1.19,1.95)
1.50
(1.12,2.01)
1.95
(1.59,2.38)
1.35
(1.07,1.71)
Unknown b na
CT diagnosis <0.01 0.86 0.17
vCT (rCT not
tested)
1 1 1
vCT (rCT
negative)
1.41
(1.08,1.84)
1.10
(0.68,1.78)
1.38
(0.90,2.11)
vCT & rCT 1.35
(1.18,1.54)
0.92
(0.73,1.16)
1.17
(0.96,1.43)
rCT (vCT
negative)
1.50
(1.16,1.93)
0.98
(0.62,1.54)
1.32
(0.89,1.97)
No. of sex partners 0.01 0.51 0.65
0 or 1 0.97
(0.83,1.14)
1.06
(0.80,1.40)
1.02
(0.80,1.31)
2 or 3 0.82
(0.72,0.94)
1.09
(0.86,1.38)
0.92
(0.75,1.14)
� 4 1 1 1
Unknown b
aOR: adjusted odds ratio; CI: confidence interval; OR: odds ratio; P: two-sided P rCT: rectal Chlamydia trachomatis, vCT: vaginal Chlamydia trachomatis
a target population includes women 18 years or older with vaginal or rectal CT and negative for HIV, syphilis, and Neisseria gonorrhoeae, during the study inclusion
period: Apr. 2016–Sept. 2017
b unknown category was included in the models (not presented)
https://doi.org/10.1371/journal.pone.0230413.t003
PLOS ONE Participation of women in prospective chlamydia research
PLOS ONE | https://doi.org/10.1371/journal.pone.0230413 March 18, 2020 10 / 17
Study evaluation
The responses on the study evaluation questionnaires in women who were retained in the
study showed a high study satisfaction (Table 5).
Discussion
We demonstrated that chlamydia-infected women can be included and retained in an inten-
sive prospective cohort with 3 months of follow-up. The FemCure study was set up to deter-
mine risks for outcomes during follow-up in a group of CT infected women. Here, we assessed
the external validity of the FemCure study, and demonstrated that the included population
was not fully representative of all STI clinic women. Due to sampling bias, women who had a
Table 4. Attrition (i.e., patients lost to follow-up or withdrawn) rates and Hazard Ratios, FemCure during the 3-month follow-up period (Apr. 2016–Dec. 2017).
Attrition events Person time at risk Incidence rate C C
n Months n/100 person months HR (95% CI) P aHR (95% CI) P
Study site 0.25
South Limburg 45 444.60 10.12 (7.38,13.54) 1
Amsterdam 41 454.44 9.02 (6.47,12.24) 0.91 (0.60,1.39)
Rotterdam 47 343.32 13.69 (10.06,18.21) 1.28 (0.85,1.93)
Age (in years) <0.01 0.03
18–20 57 319.20 17.86 (13.53,23.14) 2.15 (1.40,3.29) 1.71 (1.06,2.76)
21–23 43 463.92 9.27 (6.71,12.49) 1.25 (0.79,1.97) 1.08 (0.67,1.75)
�24 33 459.24 7.19 (4.95,10.09) 1 1
Background 0.04
Western 117 1162.08 10.07 (8.33,12.07) 1
Non-Western migrant 16 80.28 19.94 (11.39,32.37) 1.71 (1.01,2.88)
Education <0.01 <0.01
Low 68 405.48 16.77 (13.02,21.26) 2.90 (1.73,4.88) 2.36 (1.35,4.14)
Middle 47 463.20 10.15 (7.46,13.49) 1.92 (1.12,3.31) 1.48 (0.80,2.72)
High 18 370.92 4.85 (2.88,7.67) 1 1
Unknown a 0 2.76 na na Na
STI history 0.74
Yes 41 360.12 11.38 (8.47,12.91) 1
No 91 865.44 10.52 (7.42,15.45) 0.94 (0.65,1.36)
Unknown a 1 16.80 na na
Anatomic site CT diagnosed 0.47
vCT (rCT not tested) 87 770.88 11.29 (9.04,13.92) 1
vCT (rCT negative) 6 55.92 10.74 (3.94,23.35) 0.97 (0.42,2.21)
vCT & rCT 37 341.04 10.85 (7.64,10.85) 0.96 (0.66,1.42)
rCT (vCT negative) 3 74.52 4.03 (0.83,11.77) 0.40 (0.13,1.28)
No. of sex partners 0.11
0 or 1 31 278.04 11.15 (7.58,15.83) 1.42 (0.86,2.35)
2 or 3 73 569.64 12.82 (10.05,16.11)) 1.59 (10.3,2.44)
� 4 29 389.16 7.45 (4.99,10.70) 1
unknown a 0 5.52 na na
aHR: adjusted Hazard Ratio; CI: confidence interval; HR: Hazard Ratio; Na: not assessed due to low numbers in the “unknown” category; P: two-sided P; rCT: rectal
Chlamydia trachomatis, vCT: vaginal Chlamydia trachomatis
a not included in the multivariate model due to little person time in the unknown categories
https://doi.org/10.1371/journal.pone.0230413.t004
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high educational level, no STI history, or with a non-Western migrant background, were
underrepresented. We also assessed the internal validity, and concluded that the number of
retained women was sufficient for the planned analyses, but young women and less educated
women were more difficult to retain. This selective attrition may have introduced potential
selection bias, which will be taken into account when interpreting the FemCure study’s
findings.
To aid other researchers, we added a description of the strategies employed to engage
women into the study: strategies shown by previous studies to be helpful to improve inclusion
and retention (Table 1). A limitation of the current evaluation is that we could not assess the
impact of the separate strategies as we did not have a control group and all strategies were
simultaneously implemented.
To be included, women first had to be preselected, which was restricted (budgetary reasons)
by the predefined research capacity to handle inclusions. Among the preselected women, 31%
were included, which was lower than in other prospective studies in the area of sexual health
that involved women, applying self-collection of samples at home [32–34]. In FemCure, not
being able to attend the scheduled clinic visits or expecting too much effort to complete the
study were important reasons for noninclusion. Among the included women, 76% completed
the study, which was substantial and comparable to other prospective sexual health studies in
women [32–35].
The design of our study was aimed at high internal validity [1], following a large group of
women over 3 months to assess the risks for study outcomes (CT detection) after treatment.
Thereby, we were interested in including a diverse sample of women from different subsets, to
Table 5. End of follow-up study evaluation responses from the retained participants in the prospective multicen-
ter FemCure cohort study on Chlamydia trachomatis in women.
n/N = 426^ (%)
Experience with the study
Study instructions face-to-face by study nurse: (very) clear 424 (99.5)
Study instructions by website: (very) clear 318 (74.6)
Study instructions by booklet: (very) clear 407 (95.5)
Sampling: (very) easy 408 (95.8)
Communication (e.g., text messaging, email, phone): (very) satisfied 407 (95.5)
Study clinic visits: (very) satisfied 416 (97.7)
Overall experience with study: (very) good 411 (96.5)
Main reasons for participation
Contribute to more knowledge on rectal chlamydia 327 (76.8)
I could have rectal chlamydia even without anal sex 135 (31.7)
To help others 294 (69.0)
At the end of the study (week 12), to receive a chlamydia test with result and treatment (when
needed)
35 (8.2)
Monetary incentive 34 (8.0)
Awareness of rectal chlamydia
Heard of rectal chlamydia before the study 186 (43.7)
(completely) agree that is important for me to talk about rectal chlamydia:
. . . with friends/sex partners 349 (81.9)
. . . with my general practitioner or STI clinic nurse 297 (69.7)
^427 participants were retained in the study, 1 had missing evaluation data; ~measured on a 5-point Likert scale and
dichotomized for analyses (categories 4 [agree] and 5 [completely agree]—shown in the table, versus categories 1–3)
https://doi.org/10.1371/journal.pone.0230413.t005
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be able to adjust risks (confounding) and exploring heterogeneity of risks (effect
modification).
In our sample, some subgroups participated less often due to exclusion criteria and self-
selection, introducing sampling bias. The FemCure study sample underrepresented women
with a high educational level, women without STI history, and non-Western migrant women.
Women with full-time day jobs may not have had time to attend the clinic for required study
visits, contributing to the underrepresentation of highly educated women. CT-infected
women without an STI history possibly were likely less motivated to participate because of a
lower health problem awareness than the previously infected women. As a substantial number
of women with high educational level and women without STI history participated, statistical
adjustment for these variables will be possible. To be included, women should be able and will-
ing to free their time for the required clinic attendances and should understand the Dutch lan-
guage. Likely, non-Western migrant women faced language barriers to participation. The
small number of non-Western migrant women included in the study population hinders sta-
tistical adjustment for this characteristic. The diversity of our study population was, thus, con-
fined by self-selection and by exclusion criteria, such as very young (<18 years) age (ethical
reasons), recent antibiotics use, or STI co-infection (potential confounders that were expect-
edly too infrequent to statistically adjust for). The study nurses’ availability was fairly random
and thereby the restricted capacity to handle inclusions presumably did not lead to the exclu-
sion of specific subgroups. It should be noted that selective participation of any subset does
not bias the risk estimates obtained in a prospective study, as the outcomes have not yet
occurred at inclusion (they occur during follow-up) [1,14]. Further, statistical inferences to
excluded subsets will not be possible, although the risks may be applicable to such subsets [14].
Importantly, the lower participation at the Amsterdam clinic resulted from the predefined
target number of inclusions that were similar for each clinic, while the Amsterdam clinic
served a much larger number of clients (large denominator). Further, young women were gen-
erally not underrepresented as young (18–20 years of age) women were included less often but
more often preselected.
The sampling bias regarding education, no STI history, and non-Western migrant back-
ground resulted in a sample that was not completely representative of the target population.
Even though data from the clinic-based cohorts are considered more representative of the
“real world” than data from the randomized trials with numerous exclusion criteria [36], cau-
tion should be taken when making population inferences from the frequency distributions of
FemCure’s baseline characteristics. Even with a representative study sample, inferring popula-
tion impact can be a tricky undertaking as populations tend to change over time, such as STI
clinic populations that vary in composition due to policy changes. Correspondingly, STI clinic
populations may not represent the general population.
Our target number of women with retention was reached, ensuring sufficient power for the
planned analyses [15]. Retained participants expressed a high study satisfaction and it is nota-
ble that nearly all (95%) of the 452 women who completed the first follow-up measurement
were retained until the end of the study. However, young women and women with lower edu-
cational level were more difficult to retain; they tended to directly drop out after the initial
inclusion contact, as was observed in previous studies [32]. Attrition does not necessarily
invalidate the study as a sufficient number of women was still retained. However, selective
attrition may affect the internal validity when the reasons for stopping data collection were
related to both exposure and outcome [1,8]. This may introduce selection bias and lead to an
underestimation or overestimation of the risk estimates. We will examine the education and
age heterogeneity of risks by testing for effect modification, e.g., assess whether the association
between the treatment type and post-treatment CT detection differs by educational level.
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Potentially, we may consider applying probability-of-exposure weights or inverse-probability-
of-attrition weights to compensate for possible under-or-over estimation of risks [37].
By simultaneously implementing a mix of strategies, we aimed to optimize participation.
We highlight a few previously found effective components [23–34] that in our practical experi-
ence were viewed as critical for the success of this study. Training and team building have
resulted in a highly functioning and highly motivated interdisciplinary research team. Suffi-
cient staffing was a challenge with the restricted budgetary funds and was extra invested in by
the clinics. All nurses were women who at that time worked at the STI clinic in patient care
and were experienced in addressing young women with various backgrounds on sexual health
topics in a nonjudgmental way. They were committed to the protocol execution and patient
follow-ups. Patient monitoring, reminders, and data handling were managed by a logistical
team and a well-built computer program. The research was embedded in an existing clinical
infrastructure providing a trusted and familiar research environment for patients. The health
problem that this study dealt with affected the women themselves. Women received small
monetary incentives and an additional STI checkup at week 12. Data collection was made easy
with collection at home or at a nearby clinic and with clear instructions. A strategy that proved
helpful in maintaining contact was text messaging. All women received a reminder a day
before each data collection and when they did not fill in a questionnaire. Out of all women
who were retained in the study 65% (n = 278/427) had received at least one such reminder.
This proportion was 70% in retained women with a low educational level and 70% in women
aged 18–20 years. A close-contact environment was further enabled by personalized contact
with participants. Contact with study site staff was maintained by regular feedback from the
coordinating site, expressing gratitude, and addressing any issues that arose regarding the
study processes.
To conclude, it is feasible to include and retain CT-infected women in an intensive prospec-
tive cohort in busy clinical settings with sufficient investment in the design and study infra-
structure and use multifaceted strategies to maximize participation. Highly educated women,
women with non-Western background, and women without STI history were less likely to par-
ticipate, while young women and women with low educational level were more difficult to
retain.
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